• Product NameEtoricoxib
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivityEtoricoxib(MK-0663) selectively inhibited COX-2 in human whole blood assays in vitro, with an IC50 value of 1.1 0.1 μM for COX-2 (LPS-induced prostaglandin E2 synthesis), compared with an IC50 value of 116 8 μM for COX-1 (serum thromboxane B2 generation after clotting of the blood).
• Target NameCOX inhibitor
• CAS No. 202409-33-4
• Calculated MW 358.84
• Formulation C18H15ClN2O2S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Nervous system
  SMILES:CC1=NC=C(C=C1)C1=NC=C(Cl)C=C1C1=CC=C(C=C1)S(C)(=O)=O
  Pathways:Immunology/Inflammation; Neuroscience
  Receptor:COX
  Boling pt:
  Melting pt:134-135C
  Solubility:Soluble in DMSO
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Capone ML, et al. Prostaglandins Others Lipid Mediat. 2007 Jan;82(1-4):85-94.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting